Evidence map›Paper›PMID 42827988›Full record

ArticleFrontiers in microbiology2026

Insertion outside the supersite in the N-terminal domain of the SARS-CoV-2 spike glycoprotein may contribute to evasion of neutralizing antibodies.

Elena A Ermolaeva, Anastasia D Fomina, Anna N Zyrina

Abstract read
In one paragraph

Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Elena A ErmolaevaLaboratory of Biochemistry, Chumakov FSC R&D IBP RAS/Institute of Poliomyelitis, Moscow, Russia.
Anastasia D FominaLaboratory of Antivirals, Chumakov FSC R&D IBP RAS/Institute of Poliomyelitis, Moscow, Russia.
Anna N ZyrinaLaboratory of Biochemistry, Chumakov FSC R&D IBP RAS/Institute of Poliomyelitis, Moscow, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Variants of the SARS-CoV-2 virus continue to evolve. Rapidly emerging mutations, particularly in the Spike glycoprotein, may increase transmissibility and infectivity, and also lead to evasion of the immune response. The Spike protein contains two immunodominant epitopes: NTD and RBD. Numerous neutralizing antibodies against NTD are found in patient sera, and most of these target "supersite" epitopes. Consequently, mutations outside this region receive less attention. Our work continues the investigation of the effect of insertions outside the "supersite" on the phenotypic properties of SARS-CoV-2. Previously we characterized two closely related SARS-CoV-2 Delta variants differing by a 12-nucleotide insertion in the N-terminal domain of the Spike glycoprotein. In the present study, we modeled these two Spike glycoproteins and used them to perform spatial alignment analyses of S-protein structures in complex with antibodies against the NTD to assess the potential impact of the insertion on virus binding by neutralizing antibodies. We identified four potential scenarios, how the insertion can impact the binding of neutralizing antibodies targeting the NTD. Our study confirms the importance of investigating rapidly emerging mutations in the NTD, not only within the "supersite" but also beyond it. These mutations may contribute to immune evasion; consequently, their investigation is crucial for assessing the efficacy of commercially available monoclonal antibodies and vaccine preparations.

Indexed as

evasion of the immune responseglycoprotein spikehomology modelinginsertionntdSARS-CoV-2

Identifiers

PMID42827988
PMCPMC13631078

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.